Arcturus Therapeutics Holdings Inc. (ARCT)
Develops messenger RNA medicines to treat rare liver and respiratory diseases.
$5.71-0.01%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-53.6%
The outlook
ARCT is trading near its 52-week lows with analysts collectively rating it a Buy, though the stock sits below both its 50- and 200-day moving averages. The average analyst price target sits roughly 261% above the current price, reflecting bullish longer-term views despite the recent downtrend. Overall sentiment is neutral, reflecting the gap between analyst optimism and the stock's current depressed technical position.
What’s behind the score
Analyst consensusBuy — 1.5 avg of 10 analysts
Price trendBelow its 50- & 200-day averages
52-week range1% of the way from its 52-week low to high
Price targetAvg target +261% vs current price
Analyst price target
~12-month · 10 analysts$20.60average target+260.8% vs now
Now $5.71
Low $8.00High $40.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$162.3M
52-wk high
$24.17
52-wk low
$5.50
50-day avg
$6.98
200-day avg
$8.18
Trailing P/E
—